GHRH Analogue
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group attached to stabilise the molecule against enzymatic degradation. It stimulates the pituitary gland to produce endogenous growth hormone in a pulsatile, physiologically normal manner.
Mechanism of Action
Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and pulsatile release of growth hormone (GH). Unlike direct GH administration, this mechanism preserves the natural feedback regulation of the hypothalamic-pituitary axis, maintaining GH within physiological ranges.
Approved Clinical Use
Tesamorelin (Egrifta®) was approved by the FDA in 2010 for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients. It is the first and only GHRH analogue approved for clinical use in this context.
Broader Research Applications
Outside its approved indication, researchers are studying Tesamorelin in the context of age-related GH decline, muscle preservation, cognitive function in older adults, and non-alcoholic fatty liver disease (NAFLD). Early trials suggest potential benefit in improving body composition metrics in non-HIV populations.
Storage & Handling
Lyophilised Tesamorelin should be stored refrigerated at 2–8°C. It is sensitive to degradation in solution, so reconstituted peptide should be used promptly.
Research Disclaimer: Outside of its approved HIV-related indication, Tesamorelin is used as a research compound only. This content does not constitute medical advice and is for scientific education purposes.